Compare Eli Lilly And Co (LLY) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs SoundHound AI Inc — how do they compare? Eli Lilly And Co trades at $1,175.8 (market cap $1.04T), while SoundHound AI Inc trades at $5.39 (market cap $2.45B). The key difference: Eli Lilly And Co is far larger — about 424.5× SoundHound AI Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and SoundHound AI Inc for 23 Days on average.
| LLY | SOUN | |
|---|---|---|
Market Cap | $1.04T | $2.45B |
Volume | 3,064,878 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $1.28K | $21.40 |
52-Week Low | $799.57 | $5.52 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $1.09T | $2.25B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
SoundHound AI (SOUN) trades at $5.395, down 4.17% today, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth ($169M in 2025, $203M projected for 2026) but deep net losses (-$14M in 2025, -$137M projected). Recent developments include expansion into banking AI agents and the OASYS Edge embedded architecture launch for vehicles and smart devices, positioning for voice AI market growth.
Outlook is mixed: analyst consensus is bullish (75% buy ratings, $9.33 target) on growth prospects, but high valuation (P/S 11.41) and persistent losses pose risks. Key opportunities include market expansion and strategic deals; risks center on profitability, integration challenges, and competitive pressures in the AI sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
